TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02299999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Target: EGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Target: AKT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Target: HER2, EGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Target: MEK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Target: VEGF, EGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: target: Androgen receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Target: PARP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracyclines
Description: DNA intercalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracyclines
Description: DNA intercalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Target: mitotic tubulin and microtubules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Target: mitotic tubulin and microtubules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Alkylating agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Alkylating agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNA intercalators
Description: DNA intercalators

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNA intercalators
Description: DNA intercalators

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: DNA intercalators

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: DNA intercalators

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinca alkaloids
Description: Target: mitotic tubulin and microtubules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinca alkaloids
Description: Target: mitotic tubulin and microtubules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapies
Description: Platinum based chemotherapies
Study: NCT04135391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
Study: NCT04677803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide
Study: NCT02299999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapies
Description: Platinum based chemotherapies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Target: VEGF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Target: VEGF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Alkylating agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Alkylating agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Microtubule modulator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Microtubule modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Target: PD-L1
Study: NCT03576885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide
Description: inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Study: NCT01818128

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral shape of bronchial tip
Description: Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bent shape of bronchial tip
Description: Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
Study: NCT02652052

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care - Observation Only
Description: Control Arm - Observation only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Quercetin
Description: Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Dasatinib
Description: Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
Study: NCT04054193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant Dimeglumine
Description: Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonist
Description: All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
Study: NCT04096066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: * 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: - 25 mg orally on days 1-21 of each cycle.
Study: NCT00355615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: oral
Study: NCT04096066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: - 25 mg orally on days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: - 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: - 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.
Study: NCT01598753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy for FM
Description: Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Description: Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
Study: NCT02426190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill
Description: The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
Study: NCT02426190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENS - neuro-muscular stimulation
Description: The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill & PENS - neuro-muscular stimulation
Description: The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recumbent or Nu-step bike
Description: This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
Study: NCT00799045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
Study: NCT00932620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN 40 mg
Description: SIMVASTATIN 40 mg/day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN/EZETIMIBE 10/10 mg
Description: SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
Study: NCT02954419

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01956136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based Neurological Rehabilitation (MBNR)
Description: Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based Neurological Rehabilitation (MBNR)
Description: Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Description: Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Description: Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
Study: NCT02069730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR or HER2 Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-KIT Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-androgen
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOTCH Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor
Study: NCT00355615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02069730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK or PI3K Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor
Study: NCT03068416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: Autologous CD19-targeting, 3rd generation CAR T cells
Study: NCT04244864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cross-sectoral psychosocial intervention
Description: The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy.
Study: NCT00594542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
Study: NCT00694096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans
Study: NCT00725959

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online social networking HIV prevention
Description: messages about HIV posted in online social networking sites
Study: NCT02430896

Intervention type: DRUG
Intervention: Methylphenidate (MPH)
Description: Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.

Intervention type: DRUG
Intervention: Atomoxetine
Description: Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
Study: NCT00496483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCP Tacro (tacrolimus)
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
Study: NCT00953524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)
Description: 0.5 mL, Intramuscular on Day 0 and on Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
Description: 0.5 mL, Intramuscular on Day 0 and day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution (placebo)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study: NCT03023826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626 (R-Fasting)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626 (T1-Fasting)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626 (T1-Fed)
Description: Administered orally
Study: NCT04540458

Intervention type: OTHER
Group type: OTHER
Intervention: 3D printed model
Description: Mother or Mother/Father is given 3D printed model of fetus' face

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Mother or Mother/Father is given a picture of 3D ultrasound of fetus
Study: NCT02572232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combitube, Easytube, Laryngeal masks
Description: Supraglottic airway device
Study: NCT00725959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online social networking HIV prevention
Description: messages about HIV posted in online social networking sites
Study: NCT02055014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner - Endobarrier device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner - Endobarrier device
Study: NCT01093547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Samples taken monthly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Samples taken monthly
Study: NCT02142283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trevo Thrombectomy Procedure
Description: stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
Study: NCT01093547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measure of peritoneal ultrafiltrates
Description: Measured by the investigators intermittently and by the patients themselves on a monthly basis
Study: NCT02142283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
Study: NCT04359290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib administration
Description: Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.